Bedaquiline: A Novel Addition to Anti-Tubercular Armamentarium

Ruchika Nandha*1, Kamlesh Garg2, Harpal Singh3, Annu Maheshwari4*1

Ruchika Nandha*1, Kamlesh Garg2, Harpal Singh3, Annu Maheshwari4*1 *1Assistant Professor, Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Panjab University, Chandigarh , India 2Assistant Professor, Department of Clinical Research, Jamia Hamdard University, New Delhi, India 3 Consultant, Department of Critical Care, Max Superspeciality hospital, Phase 6, Mohali, India 4Department of Pharmacology, Adesh Institute of Medical Sciences, Bathinda,India

Abstract

In current scenario of rising trend of resistant tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS) co infection with TB, a novel antitubercular drug is a prime need to effectively decrease the disease burden. In lieu of the fact that no new antitubercular drug has come up in last four decades, bedaquiline (TMC 207), an arylquinoline, seems an attractive option for TB patients because of its tendency to cause earlier and sustained antitubercular action, shorten treatment duration, less chances of resistance and better safety as compared to existing second line drugs. Bedaquiline has recently been approved by USFDA on 28^thDecember, 2012 for treating multi drug resistant TB (MDR-TB) in adults ≥18 years. This review elucidates the available evidence on efficacy and safety of this drug after analyzing preclinical and clinical studies. Searches of pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like bedaquiline, TMC207 and MDR-TB.

KEY WORDS: Bedaquiline, TMC207, pulmonary tuberculosis, MDR-TB